Skip to main content
SpringerLink
Log in

Prognostic factors in Vogt-Koyanagi-Harada disease

  • Original paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To identify prognostic factors for final visual outcome, development of complications, and recurrent inflammation in patients with Vogt-Koyanagi-Harada (VKH) disease.

Methods

All patients diagnosed with acute uveitis associated with VKH disease at the King Khaled Eye Specialist Hospital and King Abdulaziz University Hospital between January 1999 and February 2004 were reviewed. Data collected included age, gender, initial and final visual acuities, clinical findings at presentation, interval between onset of disease and starting treatment, treatment received, complications, number of recurrences, extraocular manifestations, and duration of follow-up period.

Results

Sixty-eight patients were identified. There were 51 (75%) females and 17 (25%) males with a mean age of 25.04 ± 10.28 years (range 7–55 years). The mean follow-up period was 34.4 ± 20.1 months (range 8–62 months). The following factors were significantly associated with final visual acuity of 20/20 by univariate analysis: good initial visual acuity of better than 20/200 (p = 0.0415), absence of posterior synechiae of the iris at presentation (p = 0.0106), use of systemic corticosteroids for longer than nine months (p = 0.0479), slow tapering of systemic corticosteroids (p = 0.0024), absence of complications (p < 0.001), and absence of extraocular manifestations (p = 0.0124). Logistic regression analysis identified the use of systemic corticosteroids for longer than nine months to be associated with final visual acuity of 20/20 [odds ratio = 3.4; 95% confidence interval (CI) = 1.14–10.1]. The following factors were significantly associated with the development of complications by univariate analysis: age older than 18 years (p = 0.0161), initial visual acuity of 20/200 or worse (p = 0.0011), and presence of posterior synechiae of the iris at presentation (p = 0.0453). Factors identified after logistic regression analyses were age older than 18 years (odds ratio = 3.3; 95% CI = 1.33–8.17), and presence of posterior synechiae of the iris at presentation (odds ratio = 3.42; 9% CI = 1.38–8.47). Initial visual acuity of better than 20/200 was significantly associated with a lower risk of developing complications (odds ratio = 0.283; 95% CI = 0.129–0.629). The following factors were significantly associated with recurrent inflammation of three times or more by univariate analysis: initial visual acuity of 20/200 or worse (p = 0.0179), anterior chamber reaction of more than 2+ at presentation (p < 0.001), rapid tapering of systemic corticosteroids (p < 0.001), and development of extraocular manifestations (p = 0.0277).

Conclusions

Clinical findings at presentation, duration and method of tapering of systemic corticosteroids, and development of extraocular manifestations are significantly associated with final visual acuity, development of ocular complications, and recurrent inflammation. The development of ocular complications was significantly associated with a worse final visual acuity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Moorthy RS, Inomata H, Rao NA (1995) Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 39:265–292

    Article  PubMed  CAS  Google Scholar 

  2. Kobayashi H, Kokubo T, Takahashi M, Sato K, Miyokawa N, Kimura S, Kinouchi R, Katagiri M (1998) Tyrosine epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient. Immunogenetics 47:398–403

    Article  PubMed  CAS  Google Scholar 

  3. Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S (2000) Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol 165:7323–7329

    PubMed  CAS  Google Scholar 

  4. Yamaki K, Kondo I, Nakamura H, Miyando M, Konno S, Sakuragi S (2000) Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis Rats. Exp Eye Res 71:361–369

    Article  PubMed  CAS  Google Scholar 

  5. Gocho K, Kondo I, Yamaki K (2001) Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 42:2004–2009

    PubMed  CAS  Google Scholar 

  6. Imai Y, Sugita M, Nakamura S, Toriyama S, Ohno S (2001) Cytokine production and helper T cell subsets in Vogt-Koyanagi-Harada disease. Curr Eye Res 22:312–318

    Article  PubMed  CAS  Google Scholar 

  7. Abu El-Asrar AM, Struyf S, Descamps FJ, Al-Obeidan SA, Proost P, VanDamme J, Opdenakker G, Geboes K (2004) Chemokines and gelatinases in the aqueous humor of patients with active uveitis. Am J Ophthalmol 138:401–411

    Article  PubMed  CAS  Google Scholar 

  8. Read RW, Rechodouni A, Butani N, Johnston R, Labree LD, Smith RE, Rao NA (2001) Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 131:599–606

    Article  PubMed  CAS  Google Scholar 

  9. Ohno S, Minakawa R, Matsuda H (1988) Clinical studies of Vogt-Koyanagi-Harada’s disease. Jpn J Ophthalmol 32:334–343

    PubMed  CAS  Google Scholar 

  10. Ohno S, Char DH, Kimura SJ, O’Connor GR (1977) Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 83:735–740

    PubMed  CAS  Google Scholar 

  11. Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, Pivetti-Pezzi P, Tessler HH, Usui M (2001) Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 131:647–652

    Article  PubMed  CAS  Google Scholar 

  12. Forrester JV, Ben Ezra D, Nussenblatt RB, Tabbara KF, Timonen P (1994) Grading of intermediate and posterior uveitis. In: Tabbara KF, Nussenblatt RB (eds) Posterior uveitis: diagnosis and management. Butterworth-Heinemann, Boston, pp 5–18

    Google Scholar 

  13. Rubsamen PE, Gass DM (1991) Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome. Arch Ophthalmol 109:682–687

    PubMed  CAS  Google Scholar 

  14. Moorthy RS, Rajeev B, Smith RE, Rao NA (1994) Incidence and management of cataracts in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 118:197–204

    PubMed  CAS  Google Scholar 

  15. Forster DI, Rao NA, Hill RA, Nguyen QH, Baerveldt G (1993) Incidence and management of glaucoma in Vogt-Koyanagi-Harada syndrome. Ophthalmology 100:613–618

    PubMed  CAS  Google Scholar 

  16. Moorthy RS, Chong LP, Smith RE, Rao NA (1993) Subretinal neovascular membranes in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 116:164–170

    PubMed  CAS  Google Scholar 

  17. Kuo IC, Rechdouni A, Rao NA, Johnston RH, Morgolis TP, Cunningham ET Jr (2000) Subretinal fibrosis in patients with Vogt-Koyanagi-Harada disease. Ophthalmology 107:1721–1728

    Article  PubMed  CAS  Google Scholar 

  18. Sonoda S, Nakao K, Ohba N (1999) Extensive chorioretinal atrophy in Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 43:113–119

    Article  PubMed  CAS  Google Scholar 

  19. Hayasaka S, Okabe H, Takahashi J (1982) Systemic corticosteroid treatment in Vogt-Koyanagi-Harada disease. Graefe’s Arch Clin Exp Ophthalmol 218:9–13

    Article  CAS  Google Scholar 

  20. Keino H, Goto H, Usui M (2002) Sunset glow fundus in Vogt-Koyanagi-Harada disease with or without chronic ocular inflammation. Graefe’s Arch Clin Exp Ophthalmol 240:878–882

    Google Scholar 

  21. Rathinam SR, Vijayalakshmi P, Namperumalsamy P, Nozik RA, Cunningham ET Jr (1998) Vogt-Koyanagi-Harada syndrome in children. Ocul Immunol Inflamm 6:155–161

    Article  PubMed  CAS  Google Scholar 

  22. Tabbara KF, Chavis PS, Freeman WR (1998) Vogt-Koyanagi-Harada syndrome in children compared to adults. Acta Ophthalmol Scand 76:723–726

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank Ms. Connie B. Unisa-Marfil for secretarial work.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia

    Abdullah S. Al-Kharashi & Ahmed M. Abu El-Asrar

  2. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia

    Hassan Aldibhi & Hamad Al-Fraykh

  3. Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia

    Dustan Kangave

  4. Department of Ophthalmology, King Abdulaziz University Hospital, Airport Road, P.O. Box 245, Riyadh, 11411, Saudi Arabia

    Ahmed M. Abu El-Asrar

Authors
  1. Abdullah S. Al-Kharashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hassan Aldibhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hamad Al-Fraykh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dustan Kangave
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ahmed M. Abu El-Asrar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmed M. Abu El-Asrar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Al-Kharashi, A.S., Aldibhi, H., Al-Fraykh, H. et al. Prognostic factors in Vogt-Koyanagi-Harada disease. Int Ophthalmol 27, 201–210 (2007). https://doi.org/10.1007/s10792-007-9062-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-007-9062-9

Keywords

Search

Navigation